Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF


There are currently no images for PD-L1 (1019-B7).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Reactivity MuSpecies Glossary
Applications Bioactivity

Order Details

Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF Summary

Details of Functionality
Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated mouse T cells. The ED50 for this effect is 0.15-0.75 µg/mL.
Mouse myeloma cell line, NS0-derived mouse PD-L1/B7-H1 protein
Mouse PD-L1
Accession # Q9EP73
N-terminus C-terminus
Accession #
N-terminal Sequence
Structure / Form
Disulfide-linked homodimer
Protein/Peptide Type
Recombinant Proteins
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.


Theoretical MW
51.3 kDa (monomer).
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
75-85 kDa, reducing conditions
Read Publications using
1019-B7 in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS.
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF

  • Avelumab
  • B7-H
  • B7H1
  • B7-H1
  • B7H1PDCD1L1
  • CD274 antigenMGC142294
  • CD274 molecule
  • CD274
  • PDCD1L1
  • PDCD1LG1
  • PDCD1LG1MGC142296
  • PDL1
  • PD-L1
  • PD-L1B7 homolog 1
  • PDL1PDCD1 ligand 1
  • programmed cell death 1 ligand 1
  • Programmed death ligand 1


B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature mouse B7-H1 consists of a 221 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 30 aa cytoplasmic domain (2). Within the ECD, mouse B7-H1 shares 73% and 86% aa sequence identity with human and rat B7-H1, respectively. B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (2-5), keratinocytes (6, 7), enothelial and intestinal epithelial cells (6, 8), as well as a variety of carcinomas and melanoma (9, 10). B7-H1 binds to T cell B7-1/CD80 and PD-1 (5, 6, 10-13). It suppresses T cell activation and proliferation (3, 6, 12, 14) and induces the apoptosis of activated T cells (9). It plays a role in the development of immune tolerance by promoting T cell anergy (5, 12) and enhancing regulatory T cell development (14). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (3, 8) and inhibits the development of Th17 cells (14). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (4, 7, 10, 13).
  1. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
  2. Tamura, H. et al. (2001) Blood 97:1809.
  3. Chen, L. et al. (2007) J. Immunol. 178:6634.
  4. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
  5. Tsushima, F. et al. (2007) Blood 110:180.
  6. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
  7. Cao, Y. et al. (2010) Cancer Res. 71:1235.
  8. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
  9. Dong, H. et al. (2002) Nat. Med. 8:793.
  10. Azuma, T. et al. (2008) Blood 111:3635.
  11. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
  12. Park, J.-J. et al. (2010) Blood 116:1291.
  13. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
  14. Herold, M. et al. (2015) J. Immunol. 195:3584.

Customers Who Viewed This Item Also Viewed...

Species: Hu
Applications: WB, Flow, IHC, Block, CyTOF-ready, ELISA(Cap), ELISA(Det), ELISA(Sta)
Species: Hu
Applications: WB, Flow, IHC, CyTOF-ready
Species: Hu, Mu
Applications: WB, Flow, IHC, IHC-P
Species: Hu, Mu
Applications: WB, IHC
Species: Hu, Mu
Applications: WB, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Flow-IC
Species: Hu, Po
Applications: Flow, IHC, IHC-Fr, IF
Species: Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Cell Depl, CyTOF-ready, InhibTFunc
Species: Hu, Mu, Rt, Ca, Rb
Applications: WB, Simple Western, Flow, ICC/IF, IHC, IHC-Fr, IHC-P
Species: Hu, Mu, Rt
Applications: WB, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, KO
Species: Hu, Mu, Rt, Po, Bv, Eq
Applications: WB, ICC/IF, IHC
Species: Hu
Applications: WB, AgAct
Species: Hu, Mu, Rt, Bv
Applications: WB, Flow, IB, ICC/IF, IHC, IHC-P, IP, Single-Cell Western

Publications for PD-L1 (1019-B7)(15)

We have publications tested in 2 confirmed species: Mouse, N/A.

We have publications tested in 6 applications: Bioassay, ELISA (Capture), ELISA Capture, Enzyme Assay, In Vivo, Surface Plasmon Resonance.

Filter By Application
ELISA (Capture)
ELISA Capture
Enzyme Assay
In Vivo
Surface Plasmon Resonance
All Applications
Filter By Species
All Species
Showing Publications 1 - 10 of 15. Show All 15 Publications.
Publications using 1019-B7 Applications Species
S Zalba, AM Contreras-, E Martisova, R Debets, C Smerdou, MJ Garrido Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs Pharmaceutics, 2020;12(6):. 2020 [PMID: 32604843] (ELISA Capture, Mouse) ELISA Capture Mouse
LP Garo, AK Ajay, M Fujiwara, V Beynon, C Kuhn, G Gabriely, S Sadhukan, R Raheja, S Rubino, HL Weiner, G Murugaiyan Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity Cell Rep, 2019;28(13):3353-3366.e5. 2019 [PMID: 31553906] (In Vivo, Mouse) In Vivo Mouse
M Nakajima, Y Sakoda, K Adachi, H Nagano, K Tamada Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells Cancer Sci., 2019;110(10):3079-3088. 2019 [PMID: 31432594] (ELISA (Capture), Mouse) ELISA (Capture) Mouse
A von Knethe, A Schäfer, L Kuchler, T Knape, U Christen, E Hintermann, B Fi beta lthaler, K Schröder, RP Brandes, B Genz, K Abshagen, BM Pützer, LK Sha, A Weigert, SN Syed, M Schulz, AM Shah, A Ernst, M Putyrski, F Finkelmeie, M Pesic, F Greten, M Hogardt, VAJ Kempf, S Gunne, MJ Parnham, B Brüne Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis Theranostics, 2019;9(7):2003-2016. 2019 [PMID: 31037153] (In Vivo, Mouse) In Vivo Mouse
X Xue, J Wu, J Li, J Xu, H Dai, C Tao, C Li, J Hu Indirubin attenuates mouse psoriasis-like skin lesion in a CD274-dependent manner: an achievement of RNA sequencing Biosci. Rep., 2018;0(0):. 2018 [PMID: 30341238] (In Vivo, Mouse) In Vivo Mouse
H Tsukamoto, K Fujieda, A Miyashita, S Fukushima, T Ikeda, Y Kubo, S Senju, H Ihn, Y Nishimura, H Oshiumi Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment Cancer Res., 2018;0(0):. 2018 [PMID: 29967259] (Bioassay, Mouse) Bioassay Mouse
S Nakagawa, S Serada, R Kakubari, K Hiramatsu, T Sugase, S Matsuzaki, S Matsuzaki, Y Ueda, K Yoshino, T Ohkawara, M Fujimoto, T Kishimoto, T Kimura, T Naka Intratumoral delivery of an adenoviral vector carrying the SOCS-1 gene enhances T cell-mediated anti-tumor immunity by suppressing PD-L1 Mol. Cancer Ther., 2018;0(0):. 2018 [PMID: 29891489] (In Vivo, Mouse) In Vivo Mouse
J Rios-Doria, J Harper, R Rothstein, L Wetzel, J Chesebroug, AM Marrero, C Chen, P Strout, K Mulgrew, KA McGlinchey, R Fleming, B Bezabeh, J Meekin, D Stewart, M Kennedy, P Martin, A Buchanan, N Dimasi, EF Michelotti, RE Hollingswo Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies Cancer Res, 2017;0(0):. 2017 [PMID: 28283653] (In Vivo, Mouse) In Vivo Mouse
H Kinosada, JI Yasunaga, K Shimura, P Miyazato, C Onishi, T Iyoda, K Inaba, M Matsuoka HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors PLoS Pathog, 2017;13(1):e1006120. 2017 [PMID: 28046066] (N/A) N/A
Jean-Baptiste Marchand Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition Oncoimmunology, 2016;5(10):e1220467. 2016 [PMID: 27853644] (Bioassay) Bioassay
Show All 15 Publications.

Reviews for PD-L1 (1019-B7) (0)

There are no reviews for PD-L1 (1019-B7). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for PD-L1 (1019-B7) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Customers Who Bought This Also Bought

PD-L1 Antibody

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF and receive a gift card or discount.


Gene Symbol Cd274